Theraclone Sciences, Inc. Announces Initiation of a Phase 1 Clinical Trial of TCN-202, an Antibody in Development for the Treatment of Human Cytomegalovirus Infection

Published: Jun 14, 2012

SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection. While a relatively common virus, CMV transmission during pregnancy can cause permanent disabilities in children, and CMV infection can be life-threatening in individuals with weakened immune systems.

Back to news